Table of Contents Author Guidelines Submit a Manuscript
Advances in Preventive Medicine
Volume 2016, Article ID 1407840, 9 pages
http://dx.doi.org/10.1155/2016/1407840
Research Article

Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation

1Departments of Surgery, Jefferson Pancreatic, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
2Department of Biomedical Sciences, University of New England, Biddeford, ME, USA

Received 23 March 2016; Revised 29 August 2016; Accepted 23 November 2016

Academic Editor: William C. Cho

Copyright © 2016 Daniel Relles et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Padhye, S. Banerjee, A. Ahmad, R. Mohammad, and F. H. Sarkar, “From here to eternity—the secret of pharaohs: therapeutic potential of black cumin seeds and beyond,” Journal of Cancer Therapy, vol. 6, pp. 495–510, 2008. View at Google Scholar
  2. S. Banerjee, S. Padhye, A. Azmi et al., “Review on molecular and therapeutic potential of thymoquinone in cancer,” Nutrition and Cancer, vol. 62, no. 7, pp. 938–946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. C. C. Woo, A. P. Kumar, G. Sethi, and K. H. B. Tan, “Thymoquinone: potential cure for inflammatory disorders and cancer,” Biochemical Pharmacology, vol. 83, no. 4, pp. 443–451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. P. Torres, M. P. Ponnusamy, S. Chakraborty et al., “Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies,” Molecular Cancer Therapeutics, vol. 9, no. 5, pp. 1419–1431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. N. Nagi, O. A. Al-Shabanah, M. M. Hafez, and M. M. Sayed-Ahmed, “Thymoquinone supplementation attenuates cyclophosphamide-induced cardiotoxicity in rats,” Journal of Biochemical and Molecular Toxicology, vol. 25, no. 3, pp. 135–142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. O. A. Badary, M. N. Nagi, O. A. Al-Shabanah, H. A. Al-Sawaf, M. O. Al-Sohaibani, and A. M. Al-Bekairi, “Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity,” Canadian Journal of Physiology and Pharmacology, vol. 75, no. 12, pp. 1356–1361, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. G. R. Leggatt and B. Gabrielli, “Histone deacetylase inhibitors in the generation of the anti-tumour immune response,” Immunology and Cell Biology, vol. 90, pp. 33–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. M. Vigushin and R. C. Coombes, “Histone deacetylase inhibitors in cancer treatment,” Anti-Cancer Drugs, vol. 13, no. 1, pp. 1–13, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Chehl, G. Chipitsyna, Q. Gong, C. J. Yeo, and H. A. Arafat, “Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells,” HPB, vol. 11, no. 5, pp. 373–381, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Anandanadesan, Q. Gong, G. Chipitsyna, A. Witkiewicz, C. J. Yeo, and H. A. Arafat, “Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling,” Journal of Gastrointestinal Surgery, vol. 12, no. 1, pp. 57–66, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. E. Chipuk, J. C. Fisher, C. P. Dillon, R. W. Kriwacki, T. Kuwana, and D. R. Green, “Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 51, pp. 20327–20332, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. Y.-T. Hsu, K. G. Wolter, and R. J. Youle, “Cytosol-to-membrane redistribution of Bax and Bcl-XL during apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 8, pp. 3668–3672, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Westphal and H. Kalthoff, “Apoptosis: targets in pancreatic cancer,” Molecular Cancer, vol. 2, article 6, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. Z.-W. Xu, H. Friess, M. W. Büchler, and M. Solioz, “Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents,” Cancer Chemotherapy and Pharmacology, vol. 49, no. 6, pp. 504–510, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Seki, N. Ohba, R. Makino, H. Funatomi, and K. Mitamura, “Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene,” Anticancer Research, vol. 21, no. 3, pp. 1919–1924, 2001. View at Google Scholar · View at Scopus
  16. R. Ju and M. T. Muller, “Histone deacetylase inhibitors activate p21(WAF1) expression via ATM,” Cancer Research, vol. 63, no. 11, pp. 2891–2897, 2003. View at Google Scholar · View at Scopus
  17. A. A. Lane and B. A. Chabner, “Histone deacetylase inhibitors in cancer therapy,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5459–5468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Ma, H. H. Ezzeldin, and R. B. Diasio, “Histone deacetylase inhibitors: current status and overview of recent clinical trials,” Drugs, vol. 69, no. 14, pp. 1911–1934, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Lafon-Hughes, M. V. Di Tomaso, L. Méndez-Acuña, and W. Martínez-López, “Chromatin-remodelling mechanisms in cancer,” Mutation Research/Reviews in Mutation Research, vol. 658, no. 3, pp. 191–214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Schneider, O. H. Krämer, R. M. Schmid, and D. Saur, “Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma,” Journal of Gastrointestinal Cancer, vol. 42, no. 2, pp. 85–92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Miyake, T. Yoshizumi, S. Imura et al., “Expression of hypoxia-inducible factor-1α, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation,” Pancreas, vol. 36, no. 3, pp. e1–e9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Wagner, B. Hackanson, M. Lübbert, and M. Jung, “Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy,” Clinical Epigenetics, vol. 1, no. 3-4, pp. 117–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Iwahashi, M. Shimada, T. Utsunomiya et al., “Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells,” International Journal of Clinical Oncology, vol. 16, no. 6, pp. 671–678, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Donadelli, C. Costanzo, S. Beghelli et al., “Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1773, no. 7, pp. 1095–1106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Schneider, O. H. Krämer, P. Fritsche, S. Schüler, R. M. Schmid, and D. Saur, “Targeting histone deacetylases in pancreatic ductal adenocarcinoma,” Journal of Cellular and Molecular Medicine, vol. 14, no. 6 A, pp. 1255–1263, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. D. A. Richards, K. A. Boehm, D. M. Waterhouse et al., “Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study,” Annals of Oncology, vol. 17, no. 7, pp. 1096–1102, 2006. View at Publisher · View at Google Scholar · View at Scopus